A focus on PD-L1 in human melanoma

Clinical Cancer Research

Volumn 19, Issue 3, 2013, Pages 514-516

  Hersey, Peter ^a   Gallagher, Stuart ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; CANCER VACCINE; CYCLOOXYGENASE 2; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MONOCLONAL ANTIBODY; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 LIGAND 2; RAF PROTEIN; RAS PROTEIN; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOKINE RESPONSE; DRUG CYTOTOXICITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; MELANOMA; METASTATIC MELANOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; TRANSCRIPTION INITIATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE;

ANTIGENS, CD274; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84873383423     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3312     Document Type: Article

References (12)

1. Jiang X, Zhou J, Globbie-Hurder A, Wargo JA, Hodi FS. The paradoxical activation of MAPKin melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Can Res 2013;19:598-609.
2. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537-44.
3. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010;116:1757-66.
4. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28: 3167-75.
5. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:3003689.
6. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med 2012;366: 2443-54.
7. Khalili JS, Liu S, Rodriguez-Cruz TG, Whittington M, Wardell S, Liu C, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Can Res 2012;18:5329-40.
8. Kaplan FM, Shao Y, Mayberry MM, Aplin AE. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene 2011;30:366-71.
9. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7.
10. Ackerman A, McDermott D, Lawrence D, Gunturi A, Flaherty K, Giobbie-Hurder A, et al. Outcomes of patients with malignant melanoma treated with immunotherapyprior to or after vemurafenib. J Clin Oncol 30, 2012 (suppl; abstr 8569).
11. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
12. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.